CRISPR Therapeutics AG (CRSP) Accumulated Expenses (2015 - 2026)

CRISPR Therapeutics AG has disclosed Accumulated Expenses across 12 years of filings, most recently posting $4.8 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $4.8 million, down 20.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 million (down 20.52% YoY), and the FY2025 annual result was $13.0 million, down 68.43% from the prior year.
• Accumulated Expenses came in at $4.8 million for Q1 2026 at CRISPR Therapeutics AG, down from $13.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $103.0 million in Q3 2022 to a low of $4.8 million in Q1 2026.
• The 5-year median for Accumulated Expenses is $15.9 million (2023), against an average of $39.0 million.
• Across the five-year window, Accumulated Expenses surged 815.24% in 2024 and slumped 92.04% in 2025, its largest moves.
• CRISPR Therapeutics AG's Accumulated Expenses stood at $77.7 million in 2022, then slumped by 77.67% to $17.3 million in 2023, then soared by 136.77% to $41.1 million in 2024, then tumbled by 68.43% to $13.0 million in 2025, then sank by 62.69% to $4.8 million in 2026.
• The last three Accumulated Expenses figures came in at $4.8 million (Q1 2026), $13.0 million (Q4 2025), and $84.2 million (Q3 2025), per Business Quant data.